Response to "Letter to the Editor Regarding 'Matching-Adjusted Indirect Comparison of the Long-Term Efficacy Maintenance and Adverse Event Rates of Lebrikizumab vs. Dupilumab in Moderate to Severe Atopic Dermatitis'".

Rand, Kim; Ramos-Goñi, Juan Manuel; Akmaz, Bülent; Solé-Feu, Laia; Armario-Hita, José-Carlos

Rand, Kim; Ramos-Goñi, Juan Manuel; Akmaz, Bülent; Solé-Feu, Laia; Armario-Hita, José-Carlos.

Afiliación

Rand K; Maths in Health B.V., Schoolstraat 21, 6343CD, Klimmen, The Netherlands. krand@mathsinhealth.com.
Ramos-Goñi JM; Maths in Health B.V., Schoolstraat 21, 6343CD, Klimmen, The Netherlands.
Akmaz B; Global Market Access, Pricing and Medical Affairs, Barcelona, Spain.
Solé-Feu L; Global Market Access, Pricing and Medical Affairs, Barcelona, Spain.
Armario-Hita JC; Department of Dermatology, University Hospital of Puerto Real, University of Cadiz, Cádiz, Spain.

Dermatol Ther (Heidelb) ; 14(3): 823-827, 2024 Mar.

Article en En | MEDLINE | ID: mdl-38438784

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Idioma: En Revista: Dermatol Ther (Heidelb) Año: 2024 Tipo del documento: Article País de afiliación: Países Bajos Pais de publicación: Suiza

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google